Provectus Biopharma Files 2024 Annual Report Amendment
Ticker: PVCT · Form: 10-K/A · Filed: May 16, 2025 · CIK: 315545
| Field | Detail |
|---|---|
| Company | Provectus Biopharmaceuticals, Inc. (PVCT) |
| Form Type | 10-K/A |
| Filed Date | May 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
TL;DR
Provectus Biopharma filed its 2024 10-K amendment on 5/16/25. Check it for updates.
AI Summary
Provectus Biopharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on May 16, 2025, provides updated information for the company, which is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This amendment to the annual report provides updated financial and operational information for Provectus Biopharmaceuticals, Inc., crucial for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company filing an amendment to its annual report, there's inherent risk associated with regulatory approvals, clinical trial outcomes, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending December 31, 2024.)
- 20250516 — Filing Date (This amendment was filed on May 16, 2025.)
Key Players & Entities
- PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Filer
- 001-36457 (company) — SEC File Number
- 20241231 (date) — Fiscal Year End
- 20250516 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific changes or updates are included in this 10-K/A amendment?
The filing is an amendment (No. 1) to the annual report for the fiscal year ended December 31, 2024, indicating there are updates or corrections to the original filing.
What is the primary business of Provectus Biopharmaceuticals, Inc.?
Provectus Biopharmaceuticals, Inc. operates in the Pharmaceutical Preparations [2834] sector.
When was the original 10-K filed, and what is the purpose of this amendment?
The original 10-K was for the fiscal year ended December 31, 2024. This 10-K/A (Amendment No. 1) is filed to provide updated information.
Where is Provectus Biopharmaceuticals, Inc. incorporated and headquartered?
The company is incorporated in Delaware and its business address is in Knoxville, TN.
What is the SEC file number for Provectus Biopharmaceuticals, Inc.?
The Commission file number for Provectus Biopharmaceuticals, Inc. is 001-36457.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on May 16, 2025 regarding PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).